New hope for advanced stomach cancer: drug combo targets patients who failed first-line therapy
NCT ID NCT07320586
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, carilizumab and albumin paclitaxel, as a second treatment for people with advanced stomach cancer. It includes 40 adults aged 18-75 who have already tried one prior treatment, with or without immunotherapy. The goal is to see if this combo can slow cancer growth and improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shandong First Medical University Affiliated Cancer Hospital
RECRUITINGJinan, Shandong, 250021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Can surgery for stomach or esophageal cancer cloud the mind?
- Can an immunotherapy combo shrink stomach tumors before surgery?